Publications
April, 2022
OKI-179
The class I-targeting, oral HDAC inhibitor OKI-179 increases tumor regressions when combined with the MEK inhibitor binimetinib in models of NRAS melanoma
March, 2022
OKI-179
Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors
August, 2021
OKI-179
Marine Power on Cancer: Drugs, Lead Compounds, and Mechanisms
October, 2020
OKI-179
Initial results from a phase 1 trial of OKI-179, an oral Class 1-selective depsipeptide HDAC inhibitor, in patients with advanced solid tumors
October, 2020
OKI-179
Initial Results from a Phase 1 trial of OKI-179, an Oral Class 1-selective Depsipeptide HDCA Inhibitor, in Patients with Advanced Solid Tumors
January, 2020
OKI-179
HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma
October, 2019
OKI-179
OKI-179, A 1st in Class, Orally Administered HDAC Inhibitor with a Romidepsin-like Profile
August, 2019
OKI-179
Histone Deacetylase Inhibition Sensitizes PD1 Blockade–Resistant B-cell Lymphomas
February, 2019
OKI-179
Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts